Evidence map›Paper›PMID 41890686›Full record

ArticlePerspectives on behavior science2026

Reverse Translation.

Brian D Kangas

Abstract read
In one paragraph

Article in Perspectives on behavior science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Brian D KangasHarvard Medical School, McLean Hospital, Belmont, MA USA.

Funding

Neural, Cognitive and Abuse-Related Consequences of Chronic THC Exposure during Adolescence in Nonhuman PrimatesR01DA047575 · NIDA · MCLEAN HOSPITAL · PI JACK BERGMAN, Brian D. Kangas · 2019 to 2026
$5.7M
MDMA Mechanisms of Prohedonic Efficacy: A Reverse Translational ApproachR01MH136052 · NIMH · MCLEAN HOSPITAL · PI BLOUGH, BRUCE E, KANGAS, BRIAN D. · 2025 to 2025
$767k
NIDA NIH HHS R01 DA047575NIMH NIH HHS R01 MH136052
6 · The paper itself

Abstract

Stagnation in the development of novel strategies for the management of major depression and other neuropsychiatric disorders has left many patients with unmet treatment needs. This state of affairs has encouraged critical appraisal of the very relationship between preclinical findings and their clinical applications in psychiatric practice. One consequence of such reflection has been a growing emphasis on

Indexed as

AnhedoniaAnimal modelsCross-species continuityMajor depressionMedications developmentNeuropsychiatric disorders

Identifiers

PMID41890686
PMCPMC13013796

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.